To determine whether treatment with a calcium-channel blocker would improve survival and neurologic outcome in acute ischemic stroke.
- Nimodipine (Nimotop®)Drug
Intervention Desc: Calcium channel blocker (L-type calcium channels)
Prospective, double-blind, randomized, placebo-controlled trial involving 186 patients at 4 regional hospitals.
Patients were randomized to receive nimodipine (30 mg every six hours) or placebo for 4 weeks.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Matthew Scale of neurologic deficit at 28 days and death during treatment period and 6-month follow-up.|